SynthesisFrontiers in pain research (Lausanne, Switzerland)2026
Orthobiologics are not all the same: a mechanism-based scoping review of PRP, cytokine-rich serum, and extracellular vesicle-based strategies in musculoskeletal conditions.
Synthesis in Frontiers in pain research (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autologous blood-derived orthobiologics, including platelet-rich plasma and cytokine-rich serum, are widely used in musculoskeletal medicine. Extracellular vesicle-based approaches are increasingly investigated as related biologically active strategies, although they may derive from multiple autologous or allogeneic cellular and tissue sources. However, these biologics differ significantly in composition and mechanism of action, often leading to confusion in terminology and inconsistent clinical application. This scoping review critically maps current evidence (2020-2025) from randomized trials, systematic reviews, and meta-analyses to clarify the biological heterogeneity among these products. Platelet-based PRP acts primarily via growth factor release, supporting anabolic and reparative processes. Leukocyte- and monocyte-containing PRP formulations, conversely, engage immune modulation and inflammatory signaling pathways. Acellular cytokine-rich sera (e.g., autologous conditioned serum) offer immunomodulatory effects through soluble mediators like IL-1Ra. EVs and exosomes represent a promising but still experimental approach, functioning as paracrine modulators with unclear clinical efficacy. While some formulations yield similar clinical outcomes, these cannot be interpreted as biologically equivalent. The only triple-blind randomized trial on exosomes in knee osteoarthritis confirmed safety but no superiority over placebo. A mechanism-informed, indication-driven selection is essential to optimize treatment efficacy, avoid inappropriate expectations, and advance the field responsibly. This review proposes a biologically grounded classification of orthobiologics and highlights the need for standardized reporting, accurate product characterization, and rigorous clinical validation. Clinicians and researchers are urged to abandon the "one-size-fits-all" approach and embrace biological specificity when selecting orthobiologic therapies for musculoskeletal conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.